Roivant director settles taxes with 2,378 shares

A Roivant Sciences director had 2,378 shares withheld to cover taxes on vested equity awards, remaining directly holding 118,626 shares.

Rhea-AI Filing Summary

Roivant Sciences Ltd. (ROIV) director Oren Ilan reported a disposition of 2,378 Common Shares of the company on September 10, 2026. The shares were withheld by the issuer as a net settlement to cover applicable tax withholding obligations upon vesting of previously granted director equity awards. Following this tax-withholding transaction, Ilan directly holds 118,626 Common Shares of Roivant Sciences Ltd. No transactions were reported under a Rule 10b5-1 trading plan.

Insider Trade Summary

Tax Withholding: 2,378 shares

Tax Withholding 1 txn

Insider Oren Ilan

Role Director

Type	Security	Shares	Price	Value
Tax Withholding	Common Shares F1	2,378	$40.94	$97K

Holdings After Transaction: Common Shares — 118,626 shares (Direct)

Footnotes (1)

1. F1. Represents the "net settlement" by the Issuer of Common Shares previously granted to the reporting person pursuant to the Issuer's Non-Employee Director Compensation Plan in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such Common Shares.

Key Figures

Shares withheld for tax: 2,378 shares Reference share value: $40.94 per share Shares held after transaction: 118,626 shares

3 metrics

Shares withheld for tax 2,378 shares Common Shares net-settled on September 10, 2026 to satisfy tax withholding obligations

Reference share value $40.94 per share Value assigned to the 2,378 Common Shares used for tax withholding on September 10, 2026

Shares held after transaction 118,626 shares Common Shares directly held by director Oren Ilan following the September 10, 2026 transaction

Key Terms

net settlement, Non-Employee Director Compensation Plan, tax withholding obligations

3 terms

net settlement financial

"Represents the "net settlement" by the Issuer of Common Shares"

Non-Employee Director Compensation Plan financial

"previously granted to the reporting person pursuant to the Issuer's Non-Employee Director Compensation Plan"

tax withholding obligations financial

"in order to satisfy applicable tax withholding obligations in connection with the vesting"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ROIV director Oren Ilan report?

Director Oren Ilan reported a disposition of 2,378 Common Shares of Roivant Sciences Ltd. on September 10, 2026, through shares withheld by the issuer to satisfy tax withholding obligations on vested equity awards.

Was the ROIV insider transaction a market sale or tax withholding?

The transaction was not a market sale. It was a net settlement in which 2,378 shares were withheld by Roivant Sciences Ltd. to cover tax withholding obligations related to the vesting and settlement of previously granted Common Shares.

How many ROIV shares does Oren Ilan hold after this transaction?

After the September 10, 2026 tax-withholding transaction, director Oren Ilan directly holds 118,626 Common Shares of Roivant Sciences Ltd., as reported in the Form 4 filing.

At what reference price were the ROIV shares withheld for taxes?

The 2,378 Common Shares withheld from director Oren Ilan to satisfy tax obligations were valued at a reported $40.94 per share in the Form 4 filing for September 10, 2026.

Was the ROIV insider tax-withholding transaction under a Rule 10b5-1 plan?

No. The filing indicates that no Rule 10b5-1 trading plan was affirmed for the reported September 10, 2026 tax-withholding disposition of 2,378 Roivant Sciences Ltd. shares by director Oren Ilan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/14/2026 - 06:43 PM Accepted by SEC EDGAR 09/14/2026 - 06:42 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Oren Ilan

(Last) (First) (Middle)

C/O ROIVANT SCIENCES LTD.

7TH FLOOR, 50 BROADWAY

(Street)

LONDON SW1H 0DB

(City) (State) (Zip)

UNITED KINGDOM

(Country)

2. Issuer Name and Ticker or Trading Symbol
Roivant Sciences Ltd. [ ROIV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	09/10/2026		F		2,378(1)	D	$40.94	118,626	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the "net settlement" by the Issuer of Common Shares previously granted to the reporting person pursuant to the Issuer's Non-Employee Director Compensation Plan in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such Common Shares.

Remarks:

	By: /s/ Sam Kaplan, as Attorney-in-Fact for Ilan Oren	09/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)